Cochrane · systematic review · CD010081
Interventions for hidradenitis suppurativa
Ingram, JR, Woo, PN, Chua, SL, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
SkinAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
41
current version
GRADE rated
41
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 7 · 17.1%Low 11 · 26.8%Moderate 19 · 46.3%High 4 · 9.8%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Adalimumab weekly compared with placebo for hidradenitis suppurativa
Population: participants with hidradenitis suppurativa
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in DLQI score (imputation) Adalimumab weekly vs placebo | no estimate extracted | 1 study · 102 participants | Moderate Downgraded: imprecision |
Change in DLQI score (LOCF) Adalimumab weekly vs placebo | no estimate extracted | 1 study · 102 participants | Moderate Downgraded: imprecision |
Frequency of serious adverse effects Adalimumab weekly vs placebo | RR 2 [0.38, 10.44] | 1 study · 102 participants | Moderate Downgraded: imprecision |
Frequency of treatment discontinuation Adalimumab weekly vs placebo | RR 5 [0.25, 101.63] | 1 study · 102 participants | Moderate Downgraded: imprecision |
Proportion of participants with infectious adverse effects Adalimumab weekly vs placebo | RR 0.94 [0.55, 1.62] | 1 study · 102 participants | Moderate Downgraded: imprecision |
Proportion with improvement in pain VAS Adalimumab weekly vs placebo | RR 1.77 [1.02, 3.07] | 1 study · 96 participants | Moderate Downgraded: imprecision |
Change in modified Sartorius scale score (imputation) Adalimumab weekly vs placebo | no estimate extracted | 1 study · 102 participants | Moderate Downgraded: imprecision |
Adalimumab every other week compared with placebo for hidradenitis suppurativa
Population: participants with hidradenitis suppurativa
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in DLQI score (LOCF) Adalimumab every other week vs placebo | no estimate extracted | 2 studies · 124 participants | High |
Frequency of serious adverse effects Adalimumab every other week vs placebo | RR 1.47 [0.26, 8.44] | 2 studies · 124 participants | High |
Frequency of treatment discontinuation Adalimumab every other week vs placebo | RR 4.91 [0.24, 99.74] | 2 studies · 124 participants | High |
Proportion of participants with infectious adverse effects Adalimumab every other week vs placebo | RR 1.6 [0.57, 4.53] | 2 studies · 124 participants | High |
Change in Pain VAS Adalimumab every other week vs placebo | no estimate extracted | 1 study · 21 participants | Low Downgraded: imprecision, inconsistency, indirectness |
Proportion with improvement in pain Adalimumab every other week vs placebo | RR 1.34 [0.73, 2.43] | 1 study · 95 participants | Moderate Downgraded: imprecision, inconsistency, indirectness |
Change in Sartorius scale score (LOCF) Adalimumab every other week vs placebo | no estimate extracted | 2 studies · 124 participants | Moderate Downgraded: imprecision, inconsistency, indirectness |
Infliximab compared with placebo for hidradenitis suppurativa
Population: participants with hidradenitis suppurativa
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
At least 50% decrease in HS Severity Index Infliximab vs placebo | RR 4.8 [0.6, 38.48] | 1 study · 33 participants | Moderate Downgraded: imprecision |
Physician global assessment Infliximab vs placebo | RR 4.8 [1.66, 13.9] | 1 study · 33 participants | Moderate Downgraded: imprecision |
Etanercept compared with placebo for hidradenitis suppurativa
Population: participants with hidradenitis suppurativa
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Dermatology Life Quality Index Etanercept vs placebo | no estimate extracted | 1 study · 17 participants | Moderate Downgraded: imprecision |
Topical clindamycin compared with placebo for hidradenitis suppurativa
Population: participants with hidradenitis suppurativa
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Adverse effects (non‐serious) Topical clindamycin vs placebo | RR 0.72 [0.14, 3.64] | 1 study · 27 participants | Moderate Downgraded: imprecision |
Oral tetracycline compared with topical clindamycin for hidradenitis suppurativa
Population: participants with hidradenitis suppurativa
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Participant global assessment VAS Visual analogue scale (VAS) (0 to 100 mm) Oral tetracycline vs topical clindamycin | no estimate extracted | 1 study · 34 participants | Low Downgraded: risk of bias, imprecision |
Pain VAS VAS (0 to 100 mm) Oral tetracycline vs topical clindamycin | no estimate extracted | 1 study · 34 participants | Low Downgraded: risk of bias, imprecision |
Nodules score Nodule count Oral tetracycline vs topical clindamycin | no estimate extracted | 1 study · 34 participants | Low Downgraded: risk of bias, imprecision |
Abscesses score Abscess count Oral tetracycline vs topical clindamycin | no estimate extracted | 1 study · 34 participants | Low Downgraded: risk of bias, imprecision |
Physician global assessment VAS VAS (0 to 100 mm) Oral tetracycline vs topical clindamycin | no estimate extracted | 1 study · 34 participants | Low Downgraded: risk of bias, imprecision |
Ethinyloestradiol and cyproterone acetate compared with ethinyloestradiol and norgestrel for hidradenitis suppurativa
Population: participants with hidradenitis suppurativa
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants reporting non‐serious adverse effects Ethinyloestradiol and cyproterone acetate vs ethinyloestradiol and norgestrel | RR 0.53 [0.29, 0.98] | 1 study · 18 participants | Moderate Downgraded: imprecision |
Participant global assessment VAS Scale from: 0 to 100 Ethinyloestradiol and cyproterone acetate vs ethinyloestradiol and norgestrel | no estimate extracted | 1 study · 17 participants | Moderate Downgraded: imprecision |
Gentamicin sponge compared with primary closure alone for hidradenitis suppurativa
Population: participants with hidradenitis suppurativa
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Adverse effects ‐ complication rate at 1 week after surgery Gentamicin sponge vs primary closure alone | RR 0.78 [0.58, 1.05] | 1 study · 200 participants | Moderate Downgraded: risk of bias |
Adverse effects ‐ complication rate at 3 months after surgery Gentamicin sponge vs primary closure alone | RR 0.9 [0.5, 1.62] | 1 study · 200 participants | Moderate Downgraded: risk of bias |
Recurrence rate at 3 months after surgery Gentamicin sponge vs primary closure alone | RR 0.96 [0.68, 1.34] | 1 study · 200 participants | Moderate Downgraded: risk of bias |
Intense pulsed light compared with no treatment for hidradenitis suppurativa
Population: participants with hidradenitis suppurativa
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Participant global assessment: satisfaction with treatment Questionnaire Intense pulsed light vs no treatment | RR 9.67 [2.01, 46.43] | 1 study · 34 participants | Low Downgraded: risk of bias, imprecision |
Participant global assessment: satisfaction with treatment ‐ axilla Questionnaire Intense pulsed light vs no treatment | RR 21 [1.37, 322.28] | 1 study · 24 participants | Low Downgraded: risk of bias, imprecision |
Participant global assessment: satisfaction with treatment ‐ groin Questionnaire Intense pulsed light vs no treatment | RR 5 [0.31, 79.94] | 1 study · 8 participants | Low Downgraded: risk of bias, imprecision |
Participant global assessment: satisfaction with treatment ‐ inframammary Questionnaire Intense pulsed light vs no treatment | RR 3 [0.24, 37.67] | 1 study · 2 participants | Low Downgraded: risk of bias, imprecision |
Nd:YAG laser compared with topical control for hidradenitis suppurativa
Population: participants with hidradenitis suppurativa
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Modified HS‐LASI score after 3 months Nd:YAG laser vs topical control | no estimate extracted | 1 study · 50 participants | Very low Downgraded: risk of bias, imprecision |
Modified HS‐LASI score after 3 months ‐ axilla Nd:YAG laser vs topical control | no estimate extracted | 1 study · 20 participants | Very low Downgraded: risk of bias, imprecision |
Modified HS‐LASI score after 3 months ‐ groin Nd:YAG laser vs topical control | no estimate extracted | 1 study · 22 participants | Very low Downgraded: risk of bias, imprecision |
Modified HS‐LASI score after 3 months ‐ inframammary Nd:YAG laser vs topical control | no estimate extracted | 1 study · 8 participants | Very low Downgraded: risk of bias, imprecision |
Percentage change in modified HS‐LASI score after 5 months compared with baseline Nd:YAG laser vs topical control | no estimate extracted | 1 study · 50 participants | Very low Downgraded: risk of bias, imprecision |
Percentage change in modified HS‐LASI score after 5 months compared with baseline ‐ axilla Nd:YAG laser vs topical control | no estimate extracted | 1 study · 20 participants | Very low Downgraded: risk of bias, imprecision |
Percentage change in modified HS‐LASI score after 5 months compared with baseline ‐ groin Nd:YAG laser vs topical control | no estimate extracted | 1 study · 22 participants | Very low Downgraded: risk of bias, imprecision |
Niosomal methylene blue gel PDT compared with free methylene blue gel PDT for hidradenitis suppurativa
Population: participants with hidradenitis suppurativa
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
HS‐LASI score Niosomal methylene blue gel PDT vs free methylene blue gel PDT | no estimate extracted | 1 study · 20 participants | Low Downgraded: risk of bias, imprecision |
Staphage lysate compared with placebo broth for hidradenitis suppurativa
Population: participants with hidradenitis suppurativa
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Physician global assessment Staphage lysate vs placebo broth | RR 6.25 [1.68, 23.27] | 1 study · 27 participants | Moderate Downgraded: imprecision |